Oxurion NV — Major Shareholding Notification 2024

May 27, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

May 27, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – May 27, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Oxurion received a transparency notification on May 24, 2024, from Atlas Special Opportunities, LLC indicating that as of May 22, 2024, it held 2,377,763,043 shares of the then outstanding 12,275,690,851 shares, and therefore crossed above the threshold (15%) by virtue of the purchase and sell of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV	Backstage Communication
Pascal Ghoson	Jurgen Vluijmans
Chief Executive Officer	Partner
Pascal.ghoson@oxurion.com	jurgen@backstagecom.be

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

________

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer	Name OXURION
Identification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entitles)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Sulte 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in If art 7 of the Law applies)
	Name	Address (for legal entitles)
D	Please continue entering the information in part II concerning the persons referred to In Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		22/05/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		15
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	12,275,690,85
	Please enter the denominator before filling in the data
10) Notified details.
A) Voting rights	Previous notification	After the transaction
	# of voting rights	% of voting rights # of voting rights

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	1,000,850,000	2,377,763,043	0	19.37%	0.00%
	TOTAL	2.377,763,043	0	19.37%	0.00%
	Short with "ground" of bolders Add authorials with 2 . and them finish with for parnone who are "deep."

+

Start with "groupe" of holders. Add subtroling natural person or legal entity.
For groups, start with the uitimatis controlling natural person or legal entity.
The totals, au D

B) Equivalent financial Instruments	After the transaction
Holders of equivalent financial Instruments	Type of financial Instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the Instrument Is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%

The zotals will be updated once you have cilicked on «CALCULATE>

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	2,377,763,043	19.37%

11) Full chain of controlled undertakinos through which the holding is effectively held, it applicable

Atlas Special Opportunities LLC is not a controlled enfity.

12) In case of proxy voting for only one GM

	(DD/MM/YYYY)
will cease to hold / voting rights as of Holder will hold again

13) Additional information

On 2012 Will retlement called on 2 May 2024, Alas Special News LC purpased, 17,913,043 stares n Oximin Is started in Internas in 17,76,043 stares
(= 25.86%, denominator = 12,275,690,851).
On 20 May 2024 will setterner date of 2 Nay 2024, Mas Special Operation N., as a result of which its stareholing becessed o 2,37,76,043 hares (-
19.37%, denominator = 12,275,690,851).

Patrick Vance Signature - Factorial Life (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (

For security reasons, the unsigned form in xlsx format should be
transmitted to Irp.fin@tsma.be. You can do this manually
OR if you have MS Outlook at your disposal via the "

In addition, a signed copy in EDE format should also be
transmitted.

Attachment

• NL